Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Cogstate Ltd ( (AU:CGS) ) has shared an update.
Cogstate Ltd has announced a new application for the quotation of securities on the Australian Securities Exchange (ASX). The company is set to quote a total of 148,220 ordinary fully paid securities, with various issue dates in May and June 2025. This move is part of the company’s strategy to enhance its market presence and potentially increase liquidity for its stakeholders.
The most recent analyst rating on (AU:CGS) stock is a Buy with a A$1.45 price target. To see the full list of analyst forecasts on Cogstate Ltd stock, see the AU:CGS Stock Forecast page.
More about Cogstate Ltd
Cogstate Ltd operates in the healthcare industry, focusing on cognitive science and technology. The company provides cognitive assessment services and tools, primarily targeting clinical trials and healthcare research markets.
YTD Price Performance: 33.49%
Average Trading Volume: 114,946
Technical Sentiment Signal: Buy
Current Market Cap: A$235.4M
For detailed information about CGS stock, go to TipRanks’ Stock Analysis page.